An urgent need to further understand this disease
Acute leukaemia is the most common form of childhood cancer, and its incidence is increasing.
Only six out of every 10 children diagnosed with acute myeloid leukaemia (AML) will be expected to survive for more than 5 years.
These poor outcomes are further complicated by the severe therapy-associated side effects that children often experience during current treatments.
There is therefore an urgent need to further understand this disease and to develop new treatments that are both more effective and less toxic.
We need your support
With your support, we can further develop this research - saving even more lives from cancer.
Dr Kyle Matchett and his team of researchers are leading a number of pioneering research projects aimed at finding more effective and kinder ways of treating children suffering from AML.
Supporting this research will help to get targeted treatments to such children much more quickly as well as developing further treatments for similar kinds of blood cancers in the future.
Your support could help Dr Matchett's ground-breaking research, including his current work seeking to identify new drug combinations. It could transform a child’s life.